SillaJen, Inc.
Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Advanced Solid TumorTNBC - Triple-Negative Breast CancerGastric CancerLeukemia Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- SillaJen, Inc.
- Target Recruit Count
- 260
- Registration Number
- NCT05768932
- Locations
- 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States
🇺🇸University of Miami Health System, Coral Gables, Florida, United States
🇺🇸Montefiore Medical Center, Bronx, New York, United States
A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma
- Conditions
- Renal Cell Carcinoma
- First Posted Date
- 2017-09-26
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- SillaJen, Inc.
- Target Recruit Count
- 89
- Registration Number
- NCT03294083
- Locations
- 🇺🇸
Site 2644 University of California, Irvine, Irvine, California, United States
🇺🇸Site 2641 University of Miami, Miami, Florida, United States
🇺🇸Site 2643 Washington University, Saint Louis, Missouri, United States
Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- Biological: Pexastimogene Devacirepvec (Pexa Vec)
- First Posted Date
- 2015-09-29
- Last Posted Date
- 2020-12-16
- Lead Sponsor
- SillaJen, Inc.
- Target Recruit Count
- 459
- Registration Number
- NCT02562755
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸UC Irvine Medical Center, Orange, California, United States